Here is the document and then the deal logic. On June 2, 2026, MDA Systems Ltd. was granted US12644981B2, "System, method, and satellites for surveillance imaging and earth observation using synthetic aperture radar imaging." SAR is the imaging mode that matters most commercially: unlike optical cameras, it works at night and through cloud, which is why defense and insurance buyers pay a premium for it.
Now the part this desk cares about. When a SAR-capable earth-observation company is acquired, the headline multiple often looks rich against trailing revenue. That gap is usually the patent estate. An acquirer is not only buying this quarter's imagery contracts; it is buying the right to build a constellation around a sensor approach without litigating its way through someone else's claims. The grant classifications here sit in the G01S 13/90 SAR family — the heart of the radar-imaging art.
Daniela's standard applies: announced is not booked, and a patent is not a bid. We have no transaction to report and we are not implying one. What we are flagging is the mechanism — why EO deals price the way they do, and where in the documents the value actually lives.
The reason the IP, not the revenue, sets the price is structural. Earth-observation revenue is lumpy and contract-driven; it can be re-competed and lost. A granted SAR patent is durable for its term and travels with the company. For a corp-dev associate modeling an acquisition, the patent record is the part of the target that does not evaporate when a government customer re-tenders.
So when the next radar-imaging deal is announced and the multiple raises eyebrows, do the boring thing this newsroom always does: find the patents. A grant like MDA's is exactly the asset that explains a price the income statement won't. EdgarBeast's filing index can tell you what the public acquirer later books; the patent record tells you what it thought it was buying.